Zavesca is a drug owned by Actelion Pharmaceuticals Us Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 11, 2013. Details of Zavesca's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5525616 | Method of inhibiting glycolipid synthesis |
Jun, 2013
(11 years ago) |
Expired
|
| US5472969 | Method of inhibiting glycolipid synthesis |
May, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Zavesca is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zavesca's family patents as well as insights into ongoing legal events on those patents.
Zavesca's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zavesca's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 11, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zavesca Generic API suppliers:
Miglustat is the generic name for the brand Zavesca. 3 different companies have already filed for the generic of Zavesca, with Ani Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zavesca's generic
Alternative Brands for Zavesca
There are several other brand drugs using the same active ingredient (Miglustat) as Zavesca. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Amicus Therap Us |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Miglustat, Zavesca's active ingredient. Check the complete list of approved generic manufacturers for Zavesca
About Zavesca
Zavesca is a drug owned by Actelion Pharmaceuticals Us Inc. Zavesca uses Miglustat as an active ingredient. Zavesca was launched by Actelion in 2003.
Approval Date:
Zavesca was approved by FDA for market use on 31 July, 2003.
Active Ingredient:
Zavesca uses Miglustat as the active ingredient. Check out other Drugs and Companies using Miglustat ingredient
Dosage:
Zavesca is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG | CAPSULE | Prescription | ORAL |